Sai Life

Who are the top shareholders of the Sai Life?

The top shareholders of Sai Life include Tpg Asia Vii Sf Pte Ltd with 24.73%, promoter Mytreyi Kanumuri at 10.64%, mutual funds holding 11.54%, and foreign institutional investors at 12.36%, while individual investors own 7.69%. A small portion of promoter holdings is pledged at 2.6741%.

The top shareholders of Sai Life include a mix of institutional and individual investors. The largest public shareholder is Tpg Asia Vii Sf Pte Ltd, holding 24.73%. Among the promoters, Mytreyi Kanumuri, a partner at Marigold Partners, has the highest stake at 10.64%. Additionally, mutual funds hold 11.54% of the shares through 21 schemes, while foreign institutional investors (FIIs) account for 12.36% with 73 FIIs involved. Individual investors collectively hold 7.69% of the company. The majority of the shareholding is held by non-institutional investors, with a small portion of promoter holdings being pledged at 2.6741%.

how big is Sai Life?

As of Jun 06, Sai Life Sciences Ltd has a market capitalization of 15,316.00 Cr, with recent net sales of 1,854.06 Cr and net profit of 239.76 Cr for the last four quarters. Shareholder's funds are valued at 975.14 Cr, and total assets amount to 2,262.00 Cr.

Market Cap: <BR>As of Jun 06, Sai Life Sciences Ltd has a market capitalization of 15,316.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest 4 quarters, the company reported a sum of Net Sales of 1,854.06 Cr and a sum of Net Profit of 239.76 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: <BR>The Balance Sheet data is also on a Consolidated basis for the reporting period ending Mar'24. Shareholder's Funds are valued at 975.14 Cr, while Total Assets amount to 2,262.00 Cr.

Has Sai Life declared dividend?

No Dividend History Available

Is Sai Life overvalued or undervalued?

As of February 7, 2025, Sai Life is considered overvalued with a "very expensive" rating due to high valuation metrics like a PE ratio of 88.33 and an EV to EBITDA of 38.80, significantly exceeding its peers, despite recent stock performance outpacing the Sensex.

As of 7 February 2025, Sai Life has moved from a grade of "does not qualify" to "very expensive." The company is currently overvalued based on its high valuation metrics, including a PE ratio of 88.33, an EV to EBIT of 57.30, and an EV to EBITDA of 38.80. These figures significantly exceed those of its peers, such as Sun Pharmaceutical Industries Ltd., which has a PE ratio of 35.25 and an EV to EBITDA of 24.91, and Cipla Ltd., which boasts a much lower PE ratio of 22.99 and an EV to EBITDA of 15.93.<BR><BR>In comparison to its industry, Sai Life's valuation appears excessive, particularly when considering its PEG ratio of 0.00, indicating no growth expectations priced into the stock. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 4.16% compared to the Sensex's 1.35%, suggesting some investor optimism despite the high valuation. Overall, given the significant premium over its peers and the valuation grade, Sai Life is deemed overvalued.

Is Sai Life technically bullish or bearish?

As of June 23, 2025, the market trend is neutral with no strong signals, indicating a consolidation phase despite mildly bullish Bollinger Bands.

As of 23 June 2025, the technical trend has changed from mildly bullish to sideways. The current stance is neutral, with no strong bullish or bearish signals present. The MACD and KST indicators show no clear trend on both weekly and monthly time frames. The RSI is also indicating no signal on the weekly and monthly charts. While the Bollinger Bands are mildly bullish on the weekly, the overall lack of definitive trends in the moving averages, Dow Theory, and OBV suggests a consolidation phase. The recent price action, with a decline from the previous close, further supports this neutral outlook.

Who are the peers of the Sai Life?

Sai Life's peers include Alembic Pharma, Concord Biotech, Neuland Labs, Jubilant Pharmo, Natco Pharma, Blue Jet Health, Caplin Point Lab, Sanofi India, and Alivus Life, with varying management risk and growth ratings. Neuland Labs has the highest 1-year return at 69.64%, while Natco Pharma has the lowest at -20.35%.

Peers: The peers of Sai Life are Alembic Pharma, Concord Biotech, Neuland Labs., Jubilant Pharmo, Natco Pharma, Blue Jet Health, Caplin Point Lab, Sanofi India, and Alivus Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech and Sanofi India, while Good management risk is found at Alembic Pharma, Neuland Labs., Natco Pharma, Blue Jet Health, Caplin Point Lab, and Alivus Life, and Average management risk is noted at Jubilant Pharmo and Sai Life. Growth is rated as Excellent for Concord Biotech and Natco Pharma, Good for Sai Life, Neuland Labs., and Jubilant Pharmo, while Below Average growth is seen at Alembic Pharma, Blue Jet Health, and Alivus Life, and Average growth is noted at Caplin Point Lab. Capital Structure is Excellent for Concord Biotech, Neuland Labs., Natco Pharma, Blue Jet Health, Caplin Point Lab, and Alivus Life, while Good capital structure is observed at Sai Life and Average at Jubilant Pharmo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Neuland Labs. at 69.64%, while Natco Pharma has the lowest at -20.35%. Sai Life's 1-year return is not available for comparison. Additionally, Natco Pharma and Sanofi India have negative six-month returns.

What does Sai Life do?

Sai Life Sciences Ltd is a mid-cap pharmaceutical and biotechnology company, reporting net sales of ₹5,795 Cr and a net profit of ₹883 Cr for the quarter ending March 2025, with a market cap of ₹16,888 Cr. The company has a P/E ratio of 98.00 and a return on equity of 8.00%.

Overview:<BR>Sai Life Sciences Ltd is a mid-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Sai Life Sciences Limited was incorporated in 1999 as 'Sai Dru Syn Laboratories Limited' and later changed its name in 2003. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 5,795 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 883 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 16,888 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 98.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.08 <BR>Return on Equity: 8.00% <BR>Price to Book: 7.81 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

How has been the historical performance of Sai Life?

Sai Life experienced significant financial growth from March 2024 to March 2025, with net sales rising to 1,694.57 Cr and profit after tax increasing to 170.13 Cr. The company improved its operating profit margin to 23.94% and reduced total debt from 710.16 Cr to 128.64 Cr.

Answer:<BR>The historical performance of Sai Life shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Sai Life's consolidated net sales increased from 1,465.18 Cr in March 2024 to 1,694.57 Cr in March 2025, reflecting a strong upward trend in total operating income as well. The company's total expenditure rose to 1,288.91 Cr from 1,179.69 Cr, with notable increases in raw material costs and employee costs. Operating profit (PBDIT) improved significantly, reaching 442.44 Cr, up from 314.58 Cr, while profit before tax also saw a substantial rise to 227.70 Cr from 109.23 Cr. Consequently, profit after tax surged to 170.13 Cr compared to 82.81 Cr the previous year. The operating profit margin increased to 23.94% from 19.48%, and the PAT margin improved to 10.04% from 5.65%. On the balance sheet, total assets grew to 3,145.78 Cr from 2,262.00 Cr, driven by increases in shareholder's funds and cash reserves, which rose to 463.88 Cr from 158.80 Cr. The company also reduced its total debt significantly from 710.16 Cr to 128.64 Cr. Overall, Sai Life demonstrated robust financial growth and improved profitability in the fiscal year ending March 2025.

When is the next results date for Sai Life Sciences Ltd?

The next results date for Sai Life Sciences Ltd is 05 February 2026.

The next results date for Sai Life Sciences Ltd is scheduled for 05 February 2026.

Are Sai Life Sciences Ltd latest results good or bad?

Sai Life Sciences Ltd's latest Q3 FY26 results are strong, with a net profit increase of 86.41% year-on-year and revenue growth of 26.53%. However, the stock's high price-to-earnings ratio of 99 indicates elevated market expectations, which could pose risks if future performance does not meet them.

Sai Life Sciences Ltd's latest results for Q3 FY26 are quite strong, showcasing significant improvements across various financial metrics. The company reported a net profit of ₹100.38 crore, which is an impressive 86.41% increase year-on-year. Revenue also saw robust growth, rising by 26.53% year-on-year to ₹556.46 crore. This growth is complemented by a record-high operating margin of 33.76%, reflecting effective cost management and operational efficiency.<BR><BR>Furthermore, the profit after tax margin improved to 18.04%, up 580 basis points from the previous year, indicating enhanced profitability. The company has now achieved seven consecutive quarters of profitability, marking a significant turnaround from a loss reported in Q2 FY24.<BR><BR>While the results are strong, it’s important to note that the stock is currently trading at a high price-to-earnings ratio of 99 times trailing earnings, which suggests that the market has high expectations for continued growth. This elevated valuation could pose risks if the company fails to meet these expectations in the future.<BR><BR>Overall, the latest results reflect a positive trajectory for Sai Life Sciences, characterized by strong revenue growth, margin expansion, and improved profitability metrics. However, investors should remain cautious about the high valuation and potential volatility in the stock.

Should I buy, sell or hold Sai Life Sciences Ltd?

Why is Sai Life Sciences Ltd falling/rising?

As of 06-Feb, Sai Life Sciences Ltd's stock price is rising to Rs 849.00, up 4.66%, driven by strong financial health, significant institutional holdings, and recent positive performance metrics. The stock has outperformed its sector and shows robust growth potential despite a decline in delivery volume.

As of 06-Feb, Sai Life Sciences Ltd's stock price is rising, currently at Rs 849.00, reflecting an increase of Rs 37.8 or 4.66%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 5.09% today and has been on a consecutive gain for the last two days, accumulating a total return of 4.57% during this period. Additionally, the stock opened with a significant gain of 4.84% today and reached an intraday high of Rs 877.25, which is an increase of 8.14%.<BR><BR>The company's financial health also supports this rise, as it has demonstrated a strong ability to service its debt, evidenced by a low Debt to EBITDA ratio of 0.20 times. Furthermore, the company reported a healthy long-term growth rate in operating profit of 87.31%, with a recent growth of 21.76% leading to very positive results declared on December 25. The net sales over the last six months have grown by 30.96%, and the operating profit to interest ratio is at its highest, indicating robust financial performance.<BR><BR>Moreover, high institutional holdings at 52.81% suggest that knowledgeable investors have confidence in the company's fundamentals, which can positively influence retail investor sentiment. Despite a decline in delivery volume, which fell by 56.25% against the 5-day average, the overall liquidity remains sufficient for trading, further supporting the stock's price increase.

Which are the latest news on Sai Life?